Key result
HELIOS-B evaluates vutrisiran efficacy and safety in transthyretin-mediated amyloid cardiomyopathy.
Why the study?
ATTR amyloidosis is a life-threatening disease caused by amyloid fibril accumulation, and vutrisiran is an investigational RNA interference therapeutic in development for its treatment.
Does vutrisiran improve clinical efficacy and safety in patients with ATTR amyloidosis with cardiomyopathy?
Does vutrisiran improve clinical efficacy and safety in patients with ATTR amyloidosis with cardiomyopathy?
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“These new HELIOS-B analyses show that the clinical benefits of vutrisiran were maintained across these clinically complex patient groups, as well as in patients receiving background therapies, including TTR stabilizers and disease-modifying heart failure therapies, reinforcing both the consistency of the treatment effect and its relevance in real-world clinical practice. Taken together, these findings support the use of vutrisiran as a first-line treatment option for ATTR-CM across a broad range of patient populations.”
This paper describes the rationale and design of the HELIOS-B phase 3 study evaluating vutrisiran for ATTR amyloidosis with cardiomyopathy.
Transthyretin-mediated (ATTR) amyloidosis is a life-threatening disease caused by the accumulation of amyloid fibrils in multiple tissues. Vutrisiran, an investigational RNA interference therapeutic, is in development for treatment of ATTR amyloidosis. The rationale and design of HELIOS-B, a global
No takes yet. Share an insight, caveat, or question.
Shilling et al. (2020) studied this question. Vutrisiran is being evaluated for clinical efficacy and safety in patients with transthyretin-mediated amyloidosis with cardiomyopathy in the global Phase 3 HELIOS-B trial.
Synapse has enriched 10 related papers. Consider them for comparative context: